CeriBell, Inc (CBLL)vsNovartis AG ADR (NVS)
CBLL
CeriBell, Inc
$27.22
0.00%
HEALTHCARE · Cap: $997.83M
NVS
Novartis AG ADR
$156.86
-0.50%
HEALTHCARE · Cap: $286.29B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 55501% more annual revenue ($56.69B vs $101.96M). NVS leads profitability with a 22.5% profit margin vs -64.7%. NVS earns a higher WallStSmart Score of 51/100 (C-).
CBLL
Avoid28
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CBLL.
Margin of Safety
-67.2%
Fair Value
$93.84
Current Price
$156.86
$63.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.5% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Trading at 8.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CBLL
The strongest argument for CBLL centers on Revenue Growth, Debt/Equity. Revenue growth of 32.5% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : CBLL
The primary concerns for CBLL are Price/Book, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
CBLL profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
CBLL carries more volatility with a beta of 0.93 — expect wider price swings.
CBLL is growing revenue faster at 32.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 28/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CeriBell, Inc
HEALTHCARE · MEDICAL DEVICES · USA
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company is headquartered in Sunnyvale, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?